Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06746688 |
| Title | The Trial is a First-in-human, Phase I, Open-label, Dose-escalating Trial to Assess the Safety and Tolerability of ES2B-C001 Combined With Montanide or Without Montanide, in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Metastatic Breast Cancer |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | ExpreS2ion Biotechnologies |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | AUT |